Co-development for advanced companion diagnostics (CDx)

At Protagen, we are highly committed to in-depth profiling of patients’ immune responses using multi-parameter autoantibody signatures for patient stratification, to enable effective prognosis, prediction of therapy response, and the development of companion diagnostics (CDx). Such tests can be applied at different stages in the clinical development pipeline:

  1. Co-development of CDx starting with Phase I/II clinical trials
  2. Development of CDx after regulatory approval and market entry

We are actively involved in customized CDx programs for pharmaceutical and biotechnology companies of all sizes. These are structured as collaborative projects and strategic alliances. We offer our technology and in-depth scientific know-how for biomarker programs covering autoimmunity and other areas, to yield safer drugs for improved, personalized treatment.


While immunotherapies such as therapeutic vaccination and checkpoint inhibition hold great promise for treating cancer, they currently only work effectively on a small subset of patients. In addition, as they stimulate the immune system to target the body’s own cells, they can also trigger irAEs and even the onset of autoimmune disease.


NavigAID SLE separates and defines subgroups in Systemic Lupus Erythematosus (SLE), overcoming heterogeneity and enabling new approaches to successful drug development.

NavigAID SSc

NavigAID SSc is a new disease stratification array which separates and defines disease specific subgroup via the simple measurement of serum biomarkers.

SeroTag Platform

Protagen is uniquely positioned to synergistically combine the largest global human protein libraries with high-throughput identification of disease and treatment markers in patient samples (SeroTag to develop diagnostics and companion diagnostics.